Verastem Inc

2VSA

Company Profile

  • Business description

    Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

  • Contact

    117 Kendrick Street
    Suite 500
    NeedhamMA02494
    USA

    T: +1 781 292-4200

    E: [email protected]

    https://www.verastem.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    73

Stocks News & Analysis

stocks

Investors overly negative on undervalued ASX share

Road to profitability is in sight as management continues to take the right steps.
stocks

Reporting season preview: February 2025

As of Wednesday, 24 companies under coverage have reported; you’ll find our analysis throughout this issue.
stocks

Signs of a turnaround for undervalued ASX share

Market likes the payoff from early efforts at reining in costs.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,811.9013.20-0.15%
CAC 408,184.415.870.07%
DAX 4022,705.62192.200.85%
Dow JONES (US)44,546.08165.35-0.37%
FTSE 1008,752.6120.150.23%
HKSE22,616.234.10-0.02%
NASDAQ20,026.7781.130.41%
Nikkei 22539,174.2524.820.06%
NZX 50 Index13,068.9379.750.61%
S&P 5006,114.630.44-0.01%
S&P/ASX 2008,537.1018.70-0.22%
SSE Composite Index3,355.839.110.27%

Market Movers